Therapeutic Advances in Endocrinology and Metabolism

Papers
(The H4-Index of Therapeutic Advances in Endocrinology and Metabolism is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults273
Role of epicardial adipose tissue in diabetic cardiomyopathy through the lens of cardiovascular magnetic resonance imaging – a narrative review199
Insulin therapy among diabetic patients in rural communities of Sub-Saharan Africa: a perspective review59
Treatment of osteoporosis in the solid organ transplant recipient: an organ-based approach44
Use of serum MKRN3 and DLK1 levels in precocious puberty: association with an MKRN3 pathogenic variant35
The type 2 deiodinase Thr92Ala polymorphism and cognitive aging: current evidence and biological context31
Controversies in the management of active Charcot neuroarthropathy28
Novel therapeutic targets for metabolism-related diseases: proteomic Mendelian randomization and colocalization analyses26
Leave no bone unturned: metabolic bone disease in special populations25
Glycaemic outcomes in people living with diabetes under 65 and over 65 years old using an intermittently scanned continuous glucose monitoring system23
Differences in adherence to using removable cast walker treatment during daytime and nighttime weight-bearing activities in people with diabetes-related foot ulcers22
Antidiabetic drug and chronic respiratory disease in type 2 diabetes: a network meta-analysis and Mendelian randomization analysis21
Effectiveness of open-source Android artificial pancreas systems for glucose management in patients with type 1 diabetes: a real-world study20
Diagnostic performance of morning basal serum cortisol for assessing adrenal reserve: a single-center experience from the United Arab Emirates19
Is there a causal relationship between hypothyroidism and hyponatremia?19
Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor19
Pheochromocytoma: a changing perspective and current concepts19
Risk factor management over two decades in hospitalised patients with chronic limb-threatening ischaemia with and without diabetes mellitus18
Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes 18
2.7719669342041